PF-04995274
CAS No. 1331782-27-4
PF-04995274( PF-4995274 | TBPT )
Catalog No. M11321 CAS No. 1331782-27-4
PF-04995274 (TBPT) is a novel potent, sellective, partial agonist of 5-HT4 receptor under investigation for neurological disorders.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 64 | In Stock |
|
| 5MG | 65 | In Stock |
|
| 10MG | 120 | In Stock |
|
| 25MG | 197 | In Stock |
|
| 50MG | 343 | In Stock |
|
| 100MG | 494 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NamePF-04995274
-
NoteResearch use only, not for human use.
-
Brief DescriptionPF-04995274 (TBPT) is a novel potent, sellective, partial agonist of 5-HT4 receptor under investigation for neurological disorders.
-
DescriptionPF-04995274 (TBPT) is a novel potent, sellective, partial agonist of 5-HT4 receptor under investigation for neurological disorders.Alzheimer Disease Phase 1 Discontinued(In Vitro):PF-04995274 has EC50 values of 0.47 nM, 0.36 nM, 0.37 nM, 0.26 nM, 0.59 nM, 0.65 nM and 0.62 nM for human 5-HT4A/4B/4D/4E and rat 5-HT4S/4L/4E, respectively. PF-04995274 has Ki values of 0.36 nM, 0.46 nM, 0.15 nM, 0.32 nM and 0.3nM for human 5-HT4A/4B/4D/4E and rat 5-HT4S, respectively.(In Vivo):PF-04995274 (3-10 mg/kg; intravenous injection; for 17 days; male 129S6/SvEv mice) treatment results in prophylactic efficacy by attenuating learned fear and decreasing stress-induced depressive-like behavior.
-
In VitroPF-04995274 has EC50 values of 0.47 nM, 0.36 nM, 0.37 nM, 0.26 nM, 0.59 nM, 0.65 nM and 0.62 nM for human 5-HT4A/4B/4D/4E and rat 5-HT4S/4L/4E, respectively. PF-04995274 has Ki values of 0.36 nM, 0.46 nM, 0.15 nM, 0.32 nM and 0.3nM for human 5-HT4A/4B/4D/4E and rat 5-HT4S, respectively.
-
In VivoPF-04995274 (3-10 mg/kg; intravenous injection; for 17 days; male 129S6/SvEv mice) treatment results in prophylactic efficacy by attenuating learned fear and decreasing stress-induced depressive-like behavior. Animal Model:Male 129S6/SvEv mice (7-8 weeks) treated with contextual fear conditioning (CFC) and forced swim test (FST) Dosage:3 mg/kg, 10 mg/kg Administration:Intravenous injection; for 17 days Result:Attenuated learned fear and decreased stress-induced depressive-like behavior.
-
SynonymsPF-4995274 | TBPT
-
PathwayGPCR/G Protein
-
Target5-HT Receptor
-
Recptor5-HT Receptor
-
Research AreaNeurological Disease
-
IndicationAlzheimer Disease
Chemical Information
-
CAS Number1331782-27-4
-
Formula Weight432.5214
-
Molecular FormulaC23H32N2O6
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 100 mg/mL (231.21 mM)
-
SMILESC1CN(CCC1COC2=NOC3=C2C(=CC=C3)OC4CCOC4)CC5(CCOCC5)O
-
Chemical Name(R)-4-((4-(((4-(Tetrahydrofuran-3-yloxy)-1,2-benzisoxazol-3-yl)oxy)methyl)piperidin-1-yl)methyl)tetrahydro-2H-pyran-4-ol
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Sawant-Basak A, et al. J Pharm Sci. 2013 Sep;102(9):3277-93.
molnova catalog
related products
-
3-Hydroxy agomelatin...
3-Hydroxy agomelatine is an Agomelatine metabolite and a 5-HT2C receptor antagonist (IC50: 3.2 μM; Ki: 1.8 μM).
-
Adatanserin hydrochl...
Adatanserin hydrochloride (WY50324 hydrochloride) is a novel 5-HT(1A)/5-HT(2) receptor ligand with potential neuroprotective effects and inhibition of ischemic efflux of endogenous amino acids, which can be used in the study of depression and anxiety disorders.
-
Spiroxatrine
Spiroxatrine (R 5188) is a selective and potent 5-HT1α and α2-adrenergic dual antagonist with sedative activity, and inhibitory effects on 5-HT1α, 5-HT1β, 5-HT2, and dopamine receptors.
Cart
sales@molnova.com